Repligen, University of Michigan, Harvard University, Merck, Lentigen, University of Cambridge, GCH Capital Partners, University of Geneva, PhycoBiologics, NIAID, Vical, BioChemics, Beth Israel Deaconess Medical Center, International Stem Cell Corporation | GenomeWeb
Repligen, University of Michigan Settle Infringement Lawsuit with BMS
Repligen this week said that it has reached a settlement with Bristol-Myers Squibb in its lawsuit alleging infringement of US Patent No. 6,685,941, based on BMS’ sale of Orencia for treating rheumatoid arthritis.
The University of Michigan, a co-plaintiff in the lawsuit, and the US Department of the Navy co-own the patent, which is exclusively licensed to Repligen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.